Detalle Publicación


Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

Autores: Monteiro, C.; Miarka, L.; Perea-García, M.; Priego, N.; García-Gómez, P.; Álvaro-Espinosa, L.; de Pablos-Aragoneses, A.; Yebra, N.; Retana, D.; Baena, P.; Fustero-Torre, C.; Grana-Castro, O.; Troule, K.; Caleiras, E.; Tezanos, P.; Muela, P.; Cintado, E.; Trejo, J. L.; Sepúlveda, J. M.; González-León, P.; Jiménez-Roldán, L.; Moreno, L. M.; Esteban, O.; Pérez-Núñez, A.; Hernández-Laín, A.; Mazarico Gallego, J.; Ferrer, I.; Suárez, R.; Garrido-Martín, E. M.; Paz-Ares, L.; Dalmasso, C.; Moyal, E. C. J.; Siegfried, A.; Hegarty, A.; Keelan, S.; Vareslija, D.; Young, L. S.; Mohme, M.; Goy, Y.; Wikman, H.; Fernández-Alén, J.; Blasco, G.; Alcázar, L.; Cabañuz, C.; Grivennikov, S. I.; Ianus, A.; Shemesh, N.; Faria, C. C.; Lee, R.; Lorigan, P.
Título de la revista: NATURE MEDICINE
ISSN: 1078-8956
Volumen: 28
Número: 4
Páginas: 752 - 765
Fecha de publicación: 2022
A comprehensive analysis of models of brain metastasis and multiple cohorts of patient samples identifies a targetable molecular mechanism underlying the resistance to whole-brain radiotherapy that can inform patient selection for personalized radiotherapy. Whole-brain radiotherapy (WBRT) is the treatment backbone for many patients with brain metastasis; however, its efficacy in preventing disease progression and the associated toxicity have questioned the clinical impact of this approach and emphasized the need for alternative treatments. Given the limited therapeutic options available for these patients and the poor understanding of the molecular mechanisms underlying the resistance of metastatic lesions to WBRT, we sought to uncover actionable targets and biomarkers that could help to refine patient selection. Through an unbiased analysis of experimental in vivo models of brain metastasis resistant to WBRT, we identified activation of the S100A9-RAGE-NF-kappa B-JunB pathway in brain metastases as a potential mediator of resistance in this organ. Targeting this pathway genetically or pharmacologically was sufficient to revert the WBRT resistance and increase therapeutic benefits in vivo at lower doses of radiation. In patients with primary melanoma, lung or breast adenocarcinoma developing brain metastasis, endogenous S100A9 levels in brain lesions correlated with clinical response to WBRT and underscored the potential of S100A9 levels in the blood as a noninvasive biomarker. Collectively, we provide a molecular framework to personalize WBRT and improve its efficacy through combination with a radiosensitizer that balances therapeutic benefit and toxicity.